Igor I. Slukvin, MD, PHD
Professor, Pathology & Laboratory Medicine
- Organ System/Disease Focus:
- Blood development/disease
- Aligned Research Focus:
- Hematopoietic and endothelial development from human pluripotent stem cells, hematopoietic stem cell (HSC) biology
- Researchers forge primitive human leukemia cells in lab, 1 December 2015
- Wisconsin scientists find genetic recipe to turn stem cells to blood: 14 July 2014
- New induced stem cells may unmask cancer at earliest stage; 4 February 2011
- Additional appointments: Cell & Regenerative Biology (joint appointment); Wisconsin National Primate Center (affiliate scientist)
- Slukvin Laboratory Home Page
Pluripotent stem (PS) cells, including embryonic stem (ES) and induced pluripotent stem (iPS) cells, represent a unique population of cells capable of self-renewal and differentiation. Pluripotent stem cells can form any cell type in the body and serve as a scalable cell source for transplantation and tissue engineering. The main focus of my research is to establish the differentiation of human pluripotent stem cells into hematopoietic progenitors and mature blood cells in order to understand molecular mechanisms of early hematopoietic differentiation and provide a novel source of cells for bone marrow transplantation, transfusion and cancer immunotherapy. Recently we developed methods for efficient differentiation of PS cells into myelomonocytic and erythroid cells and identified the hierarchy of mesodermal and hematoendothelial progenitors leading to the formation of blood cells and hematopoiesis-supportive elements. In addition, we developed technologies for efficient reprogramming of normal and neoplastic blood cells into iPS cells. Currently my laboratory is working on 1) identification of genes essential for acquisition of long-term engraftment potential by pluripotent stem cell-derived hematopoietic cells; 2) establishing non-human primate models of ES cell and iPS cell-based cellular therapy for blood and immune system disorders; 3) developing iPS cell based models for blood cancer stem cell development.
- Kang HJ, Mesquitta WT, Jung HS, Moskvin OV, Thomson JA and Slukvin II. GATA2 is Dispensable for Specification of Hemogenic Endothelium but Promotes Endothelial-to-Hematopoietic Transition. Stem Cell Reports [Epub ahead of print].
- Uenishi G, Jung HS, Kumar A, Park MA, Hadland BK, McLeod E, Raymond M, Moskvin O, Zimmerman CE, Theisen DJ, Swanson S, Tamplin O, Zon LI, Thomson JA, Bernstein ID and Slukvin II. NOTCH Signaling Specifies Arterial-Type Definitive Hemogenic Endothelium from Human Pluripotent Stem Cells. Nature Communications 2018 May 8;9(1):1828.
- Park MA, Kumar A, Jung HS, Uenishi G, Moskvin OV, Thomson JA, and Slukvin II. Activation of Arterial Program Drives Development of Definitive Hemogenic Endothelium with Lymphoid Potential. Cell Reports 2018 May 22, 23: 2467–2481
- Kumar A, D’Souza SS, Moskvin OV, Toh H, Wang B, Zhang J, Swanson S, Guo LW, Thomson JA, Slukvin II. Specification and Diversification of Pericytes and Smooth Muscle Cells from Mesenchymoangioblasts. Cell Rep. 2017 May 30;19(9):1902-1916.
- Kang H, Minder P, Park MA, Mesquitta WT, Torbett BE, Slukvin II. CCR5 Disruption in Induced Pluripotent Stem Cells Using CRISPR/Cas9 Provides Selective Resistance of Immune Cells to CCR5-tropic HIV-1 Virus. Mol Ther Nucleic Acids. 2015 Dec 15;4:e268.
Note: Since some names are more common than others, search may need more refining to specifically target this researcher.